Daewoong Pharmaceutical (CEO Jeon Seung-ho and Lee Chang-jae) has published an international SCIE (Science Citation Index Expanded) paper entitled ‘Europe to identify molecular mechanisms that can simultaneously explain the efficacy and safety of Persiporocin, which is being developed as a treatment for idiopathic pulmonary fibrosis It was announced on the 26th that it has been listed in the European Institute of Molecular Biology Molecular Medicine by a joint research team led by Professor Seong-Hoon Kim from Yonsei University and’ Professor Kwang-Yeon Hwang from Korea University. The title of the paper is ‘Management of fibrosis by asymmetric inhibition of prolyl-tRNA synthetase 1’.
The Journal of Molecular Medicine of the European Society of Molecular Biology is a world-renowned journal highly sought after by related researchers for publication and citation, with an Impact Factor (IF) of 14.005 for 2021-2022 , and is a journal within the top 5% in this field.
Versiphorosin, which is being developed by Daewoong Pharmaceutical, exhibits therapeutic effects by inhibiting the activity of the enzyme PARS1 (Prolyl-tRNA Synthetase1) which promotes collagen synthesis. Meanwhile, researchers from all over the world have tried to treat pulmonary fibrosis by regulating the activity of PRS, but since the PARS1 enzyme is essential for the maintenance of life, excessive inhibition of activity can lead to side effects, making it difficult to develop new drugs. Therefore, inhibiting PARS1 enzyme activity to a level that is safe for patients while maintaining the therapeutic effect has been a key task for new drug development.
Through this study, the company explains that versiphorosin, by binding a pair of PARS1 enzymes asymmetrically, does not cause excessive activity inhibition, thereby reducing the drug’s side effects while exhibiting efficacy.
“To make precision medicine a reality and to ensure the ability to develop new drugs on a global level, there is an urgent need to find new drug targets with new mechanisms,” said Sung-Hoon Kim, professor at Yonsei University and corresponding author of this study It is also significant that this study proves that the same essential enzymes can also be used as targets for the development of new drugs.”
Park Joon-seok, head of Daewoong Pharmaceutical’s New Drug Discovery Center, said, “Daewoong Pharmaceutical’s self-developed versiphorosin has achieved important research results that can explain efficacy and safety through this study.” We hope to provide new treatment options for suffering patients. from rare diseases.”
